World-leading CAR-T cell therapy technology, providing innovative treatment solutions specifically for patients with refractory multiple myeloma, lymphoma, and leukemia
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is a revolutionary cancer immunotherapy that genetically engineers a patient’s own T cells to precisely recognize and attack cancer cells.
We focus on providing world-leading CAR-T therapy services for patients with relapsed/refractory multiple myeloma (RRMM), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL).
Leveraging China’s advanced advantages in CAR-T research, development, and clinical application, we provide global patients with one-stop services ranging from consultation and assessment, medical visas, and treatment arrangements to recovery follow-up.
CAR-T cells can specifically recognize tumor antigens and precisely attack cancer cells, maximizing the protection of normal tissues and reducing the side effects of traditional chemotherapy.
Clinical data shows that BCMA CAR-T therapy for relapsed/refractory multiple myeloma achieves an Overall Response Rate (ORR) of 98.9% and a Complete Response Rate (CR) of 82.4%, with a median duration of response of 419 days.
· We are a CAR-T treatment center approved by the National Medical Products Administration (NMPA), and all treatments are conducted in JCI-accredited hospitals.
· As of 2024, six CAR-T products have been approved for market in China, including the world’s first fully human BCMA CAR-T product, Fucaso® (Equecabtagene Autoleucel Injection).
· Our medical team is composed of experts in hematology, oncology, and immunotherapy with extensive clinical experience in CAR-T therapy
Led by internationally renowned hematologic oncology experts, providing personalized treatment plans.
From medical consultation and visa processing to treatment arrangements and recovery follow-up, we provide a seamless one-stop service.
Compared to Europe and the United States, China’s CAR-T treatment costs are more competitive while ensuring equivalent medical quality.
Arrange treatment quickly to buy precious time for patients with urgent conditions.
From Despair to Rebirth in Just 22 Days! A Thai patient with late-stage multiple myeloma achieved complete remission and a new lease on life after receiving CAR-T treatment in China.
